In recent years, my country’s biomedical industry has developed rapidly, but the failure to master some important original equipment, reagents and key biological technologies has affected the overall innovation capability and level of the biomedical field. Shangguan Xinchen, member of the National Committee of the Chinese People’s Political Consultative Conference and director of the Provincial Drug Administration, suggested to increase financial support for downstream applied research and the transformation of diversified results, increase support for the construction of independent research and development capabilities of modern pharmaceutical companies, and establish national-level demonstration applications. effect technology platform. At the same time, a national biomedical innovation park will be established to maximize the win-win cooperation of various innovation entities and the high-standard construction of biomedical innovation capability bases, and promote the formation of a comprehensive and efficient innovation system.
Shangguan Xinchen also suggested that the national and provincial drug review and approval systems should be resonated at the same frequency as pharmaceutical innovation, continue to deepen drug regulatory reform, establish more efficient and transparent regulatory rules, and effectively reduce institutional transaction costs. , to better stimulate the vitality of pharmaceutical innovation and promote the high-quality development of the pharmaceutical industry.
Our reporter Liu Fei